¼¼°èÀÇ ½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ½ÃÀå
Post-Marketing Pharmacovigilance and Medical Information
»óǰÄÚµå : 1777459
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 9Á¶ 6,000¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6Á¶ ´Þ·¯·Î ÃßÁ¤µÇ´Â ½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 9Á¶ 6,000¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÚ¹ß º¸°í ¼­ºñ½º´Â CAGR 10.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4Á¶ 2,000¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °­È­Çü ADR º¸°í ¼­ºñ½º ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 7.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1Á¶ 6,000¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ½ÃÀåÀº 2024³â¿¡´Â 1Á¶ 6,000¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2Á¶ 1,000¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 13.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 4.1%¿Í 8.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¦¾à »ê¾÷¿¡¼­ ½ÃÆÇ ÈÄ ¾à¹°°¨½Ã°¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

½ÃÆÇ ÈÄ ¾à¹°°¨½Ã(PV)´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ÈÄ ÀǾàǰÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ½ÇÁ¦ »ç¿ë ½Ã ÀǾàǰÀÇ ÀáÀçÀû À§Çè, ºÎÀÛ¿ë(AE), Àå±âÀû ¿µÇâ¿¡ ´ëóÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÓ»ó½ÃÇèÀº Ãʱ⠾ÈÀü¼º µ¥ÀÌÅ͸¦ Á¦°øÇÏ´Â ¹Ý¸é, Ç¥º» Å©±â, ȯÀÚ ´Ù¾ç¼º, ±â°£ÀÌ Á¦ÇÑÀûÀÎ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ½ÃÆÇ ÈÄ Á¶»ç´Â µå¹°°Å³ª Áö¿¬µÇ°Å³ª ¿¹»óÄ¡ ¸øÇÑ ºÎÀÛ¿ëÀ» °¨ÁöÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. FDA(¹Ì±¹), EMA(À¯·´), MHRA(¿µ±¹), PMDA(ÀϺ») µîÀÇ ±ÔÁ¦±â°üÀº Á¦¾àȸ»ç°¡ ÀǾàǰÀÇ ¶óÀÌÇÁ»çÀÌŬ Àü¹Ý¿¡ °ÉÃÄ À§ÇèÀ» Æò°¡, º¸°í, ¿ÏÈ­ÇÒ ¼ö ÀÖµµ·Ï Áö¼ÓÀûÀÎ ÀǾàǰ ¾ÈÀü¼º ¸ð´ÏÅ͸µÀ» Àǹ«È­Çϰí ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ Ä¡·áÁ¦, ¸ÂÃãÇü ÀǾàǰÀÇ º¹À⼺À¸·Î ÀÎÇØ °íµµÀÇ ¾à¹°°¨½Ã Àü·«ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½ÃÆÇ ÈÄ Á¶»ç´Â ÀÚ¹ßÀû º¸°í ½Ã½ºÅÛ(SRS), ÀüÀڰǰ­±â·Ï(EHR) ¸ð´ÏÅ͸µ, ´Éµ¿Àû Á¶»ç, ºòµ¥ÀÌÅÍ ºÐ¼® µîÀ» ÅëÇØ ¾à¹°ÀÇ ½ÇÁ¦ ¼º´ÉÀ» ÃßÀûÇÕ´Ï´Ù. ¶ÇÇÑ Á¦¾à»ç´Â ÀÇ·áÀÎ(HCP), ȯÀÚ, ±ÔÁ¦ ´ç±¹¿¡ Á¤È®ÇÏ°í ±Ù°Å¿¡ ±â¹ÝÇÑ ´äº¯À» Á¦°øÇϰí, ÀǾàǰ ¾ÈÀü¼º Á¤º¸ Àü´Þ¿¡ ÀÖ¾î ÄÄÇöóÀ̾𽺠¹× Åõ¸í¼ºÀ» º¸ÀåÇϱâ À§ÇØ ÀÇ·áÁ¤º¸(MI) ¼­ºñ½º¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ½ÃÆÇ ÈÄ ¾à¹°°¨½Ã¸¦ ¾î¶»°Ô °­È­Çϴ°¡?

ÀΰøÁö´É(AI), ¸Ó½Å·¯´×(ML), ºòµ¥ÀÌÅÍ ºÐ¼®, ÀÚ¿¬¾î ó¸®(NLP) µîÀÇ ±â¼ú Çõ½ÅÀº ºÎÀÛ¿ë °ËÃâÀÇ ¼Óµµ, Á¤È®¼º, ÀÚµ¿È­¸¦ °³¼±ÇÏ¿© ¾à¹°°¨½Ã ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¾Ë°í¸®ÁòÀº ÀüÀÚÀǹ«±â·Ï, ¼Ò¼È ¹Ìµð¾î Åä·Ð, ȯÀÚ º¸°í¿¡ ÀÇÇÑ °á°ú¸¦ ºÐ¼®ÇÏ¿© ±âÁ¸ÀÇ ¼öÀÛ¾÷ °ËÅä ÇÁ·Î¼¼½ºº¸´Ù ´õ È¿À²ÀûÀ¸·Î ÀáÀçÀûÀÎ ¾ÈÀü¼º ½ÅÈ£¿Í »õ·Î¿î ¾à¹° °ü·Ã À§ÇèÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Å« ¹ßÀüÀº ½ÃÆÇ ÈÄ ¾ÈÀü¼º Á¶»ç¿¡¼­ ¸®¾ó¿ùµå¿¡ºñ´ø½º(RWE)¿Í ÀüÀڰǰ­±â·Ï(EHR)ÀÇ ÅëÇÕÀÔ´Ï´Ù. Á¦¾àȸ»ç¿Í ±ÔÁ¦ ´ç±¹Àº RGlobal Industry AnalystsÀÇ ºÐ¼®À» Ȱ¿ëÇÏ¿© º¸´Ù ±¤¹üÀ§ÇÑ È¯ÀÚ Áý´Ü¿¡¼­ Àå±âÀûÀÎ ¾ÈÀü¼º °á°ú, ÀûÀÀÁõ ¿Ü »ç¿ë À§Çè, ¾à¹°-¾à¹° »óÈ£ÀÛ¿ëÀ» Æò°¡Çϱâ À§ÇØ Á¡Á¡ ´õ ¸¹Àº Á¦¾àȸ»ç¿Í ±ÔÁ¦ ´ç±¹ÀÌ RGlobal Industry AnalystsÀÇ ºÐ¼®À» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®´Â ÀǾàǰÀÇ ¶óº§ ¾÷µ¥ÀÌÆ®, ½ÃÀå ö¼ö, À§Çè °¨¼Ò Àü·«¿¡ ´ëÇÑ µ¥ÀÌÅÍ ±â¹Ý ÀÇ»ç°áÁ¤¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Ŭ¶ó¿ìµå ±â¹Ý ¾à¹°°¨½Ã Ç÷§Æû°ú ÀÚµ¿È­ µµ±¸´Â »ç·Ê °ü¸®, ½ÅÈ£ °¨Áö, ±ÔÁ¦ ´ç±¹¿¡ ´ëÇÑ º¸°í¸¦ °­È­ÇÕ´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ Å¬¶ó¿ìµå ±â¹Ý ºÎÀÛ¿ë(AE) °ü¸® ½Ã½ºÅÛÀ» äÅÃÇÏ¿© ½Ç½Ã°£ ºÎÀÛ¿ë º¸°í, ÀÚµ¿È­µÈ »ç·Ê ó¸®, °£¼ÒÈ­µÈ ¼¼°è ¾ÈÀü ±ÔÁ¤ Áؼö¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ ¾ÈÀü¼º µ¥ÀÌÅÍ °ü¸®¿¡ ºí·ÏüÀÎ ±â¼úÀ» µµÀÔÇÔÀ¸·Î½á µ¥ÀÌÅÍÀÇ ¹«°á¼º, º¸¾È, ÃßÀû¼ºÀ» Çâ»ó½Ã۰í, º¯Á¶ ¹æÁöµÈ ¾à¹°°¨½Ã ±â·ÏÀ» º¸ÀåÇÕ´Ï´Ù.

ÆÄ¸¶ÄÚºñÁ¯ ¹× ÀÇ·áÁ¤º¸ ¼­ºñ½º È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ½ÃÀå µ¿ÇâÀº ¹«¾ùÀΰ¡?

¾à¹°°¨½Ã »ê¾÷À» Çü¼ºÇÏ´Â °¡Àå Áß¿äÇÑ Æ®·»µå Áß Çϳª´Â ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã °­È­¿Í ÄÄÇöóÀ̾𽺠¿ä±¸»çÇ×ÀÇ ÁøÈ­ÀÔ´Ï´Ù. Àü ¼¼°è ±ÔÁ¦ ±â°üµéÀº º¸´Ù ¾ö°ÝÇÑ º¸°í ÀÏÁ¤, Åõ¸í¼º Àǹ«È­, ¸®½ºÅ© ÃÖ¼ÒÈ­ Àü·«À» ¿ä±¸Çϰí ÀÖÀ¸¸ç, Á¦¾à»çµéÀº AI ±â¹ÝÀÇ ÀÚµ¿È­µÈ ¾à¹°°¨½Ã ½Ã½ºÅÛÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¾à¹°°¨½Ã °èȹ¿¡ ´ëÇÑ ICH E2E °¡À̵å¶óÀΰú ISO IDMP(Identification of Medicinal Products) Ç¥ÁØÀÇ µµÀÔÀº ÅëÇÕ ¾ÈÀü¼º µ¥ÀÌÅÍ °ü¸® Ç÷§Æû¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ȯÀÚ Áß½ÉÀÇ ¾à¹°°¨½Ã¿Í µðÁöÅÐ °Ç°­ ¸ð´ÏÅ͸µÀÇ ºÎ»óµµ Å« È帧ÀÔ´Ï´Ù. ¸ð¹ÙÀÏ Çコ(¸ð¹ÙÀÏ Çコ), ¿þ¾î·¯ºí ±â±â, ȯÀÚ »ý¼º °Ç°­ µ¥ÀÌÅÍ(PGHD)ÀÇ È®´ë·Î ÀǾàǰ ¾ÈÀü¼º ¸ð´ÏÅ͸µÀº ´õ¿í ´Éµ¿ÀûÀÌ°í ½Ç½Ã°£À¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº Áö¼ÓÀûÀÎ ¾ÈÀü¼º µ¥ÀÌÅÍ ¼öÁýÀ» À§ÇØ ½º¸¶Æ®Æù ¾Û, ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­, ¿Â¶óÀΠȯÀÚ µî·ÏÀ» ÅëÇØ À§ÇèÀ» Á¶±â¿¡ ¹ß°ßÇÏ°í °³º°È­µÈ ¾à¹°°¨½Ã Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ¼­ºñ½º¸¦ CRO(ÀǾàǰ °³¹ß ¼öʱâ°ü) ¹× BPO(ºñÁî´Ï½º ÇÁ·Î¼¼½º ¾Æ¿ô¼Ò½Ì) Á¦°ø¾÷ü¿¡ ¾Æ¿ô¼Ò½ÌÇÏ´Â °Íµµ Áß¿äÇÑ Æ®·»µåÀÔ´Ï´Ù. ºÎÀÛ¿ë(AE) »ç·Ê º¸°í, ¾ÈÀü¼º ½ÅÈ£ Æò°¡, ±ÔÁ¦ ´ç±¹¿¡ Á¦ÃâÇÏ´Â »ç·Ê°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¸¹Àº Á¦¾à»çµéÀÌ ½ÃÆÇ ÈÄ ¾ÈÀü¼º ¾÷¹«¸¦ Àü¹® PV ¼­ºñ½º Á¦°ø¾÷ü ¹× ±â¼ú °ø±Þ¾÷ü¿¡ ¾Æ¿ô¼Ò½ÌÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾Æ¿ô¼Ò½Ì ¸ðµ¨Àº ±ÔÁ¦ Áؼö¿Í µ¥ÀÌÅÍ ±â¹Ý ÀÇ»ç°áÁ¤À» º¸ÀåÇÏ´Â µ¿½Ã¿¡ ¿î¿µ ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀϱî?

½ÃÆÇ ÈÄ ¾à¹°°¨½Ã ¹× ÀÇ·áÁ¤º¸ ½ÃÀåÀÇ ¼ºÀåÀº ºÎÀÛ¿ë(ADR) ¹ß»ý·ü Áõ°¡, AI¸¦ Ȱ¿ëÇÑ ¾ÈÀü¼º ¸ð´ÏÅ͸µ µµÀÔ Áõ°¡, ¼¼°è ¾à¹°°¨½Ã ±ÔÁ¦ È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â »õ·Î ½ÂÀÎµÈ ÀǾàǰ, ¹ÙÀÌ¿À½Ã¹Ð·¯, º´¿ë¿ä¹ýÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ÀǾàǰÀº Àå±âÀûÀÎ ¾ÈÀü¼º°ú ¾à¹°°¨½Ã ¹ý±Ô Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ ½ÃÆÇ ÈÄ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÏ´Ù´Â Á¡ÀÔ´Ï´Ù.

¶Ç ´Ù¸¥ ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¸ÂÃãÇü ÀÇ·á¿Í »ý¹°ÇÐÀû Á¦Á¦ÀÇ È®´ë·Î, À̵é ÀǾàǰÀº Ç¥ÀûÈ­µÈ ÀÛ¿ë ±âÀü°ú ȯÀÚº° Ä¡·á ¹ÝÀÀÀ¸·Î ÀÎÇØ °íÀ¯ÇÑ ¾ÈÀü¼º À̽´°¡ Á¸ÀçÇÕ´Ï´Ù. ¼¼Æ÷ Ä¡·áÁ¦, À¯ÀüÀÚ Ä¡·áÁ¦, ¸é¿ªÄ¡·áÁ¦, °íÁ¤¹Ð ¾Ï Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀÌ È®´ëµÊ¿¡ µû¶ó, À¯Àüü ¹× ¹ÙÀÌ¿À¸¶Ä¿ Áß½ÉÀÇ ¾à¹°°¨½Ã µ¥ÀÌÅ͸¦ ÅëÇÕÇϴ ÷´Ü ¾ÈÀü¼º ¸ð´ÏÅ͸µ ¸ðµ¨¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀǾàǰ ¾ÈÀü ±ÔÁ¦¿¡ ´ëÇÑ ¼¼°è Á¶È­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀ» ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ±â°üµéÀº ºÎÀÛ¿ëÀÇ Å½Áö ¹× ½ÅÈ£ °ü¸®¸¦ °³¼±Çϱâ À§ÇØ Ç¥ÁØÈ­µÈ PV ÇÁ·¹ÀÓ¿öÅ©, µðÁöÅÐ º¸°í Æ÷ÅÐ, ±¹°æ °£ ¾ÈÀü µ¥ÀÌÅÍ °øÀ¯¸¦ À§ÇØ Çù·ÂÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ¿©·¯ ±¹°¡¿¡¼­ ÁøÈ­ÇÏ´Â ¾à¹°°¨½Ã ¹ý±Ô¸¦ ÁؼöÇØ¾ß Çϱ⠶§¹®¿¡ ÀÚµ¿È­µÈ ÄÄÇöóÀ̾𽺠Ç÷§Æû, ±ÔÁ¦ Á¤º¸ µµ±¸, ¾ÈÀü¼º µ¥ÀÌÅͺ£À̽ºÀÇ Áß¾ÓÁýÁßÈ­¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¾à¹°°¨½ÃÀÇ ºÎ»óÀº ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Áß±¹, Àεµ, ºê¶óÁú, Çѱ¹ µîÀÇ ±¹°¡¿¡¼­´Â ±¹°¡ Â÷¿øÀÇ ¾à¹°°¨½Ã ÇÁ·Î±×·¥ÀÌ °­È­µÇ°í ÀÖÀ¸¸ç, ±¹³»¿¡¼­ Á¦Á¶µÈ ÀǾàǰ°ú ¼öÀÔµÈ ÀǾàǰ ¸ðµÎ¿¡ ´ëÇØ º¸´Ù ¾ö°ÝÇÑ ½ÃÆÇ ÈÄ Á¶»ç¸¦ Àǹ«È­Çϰí ÀÖ½À´Ï´Ù. Áö¿ªº°·Î ƯȭµÈ PV Àü¹®¼º, ´Ù±¹¾î ¾ÈÀü¼º º¸°í, Áö¿ª Ưȭ ÄÄÇöóÀ̾𽺠¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â ¾à¹°°¨½Ã ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô »õ·Î¿î ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.

½ÃÆÇ ÈÄ ¾ÈÀü¼º ¿ä°ÇÀÌ °­È­µÊ¿¡ µû¶ó Á¦¾à»çµéÀº AI ±â¹Ý ¾ÈÀü¼º ¸ð´ÏÅ͸µ, µðÁöÅÐ °Ç°­ ºÐ¼®, ȯÀÚ Áß½ÉÀÇ ¾à¹°°¨½Ã ¸ðµ¨¿¡ Áö¼ÓÀûÀ¸·Î ÅõÀÚÇÏ¿© ÀǾàǰ ¾ÈÀüÀÌ ÁøÈ­ÇÏ´Â ¼¼°è ÇコÄɾ¼­ ÃÖ¿ì¼± ¼øÀ§·Î À¯ÁöµÉ ¼ö ÀÖµµ·Ï ÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

¼­ºñ½º À¯Çü(ÀÚ¹ß º¸°í ¼­ºñ½º, °­È­Çü ADR º¸°í ¼­ºñ½º, Ÿ°Ù ÀÚ¹ß º¸°í ¼­ºñ½º, ÄÚȣƮ À̺¥Æ® ¸ð´ÏÅ͸µ ¼­ºñ½º, EHR ¸¶ÀÌ´× ¼­ºñ½º), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿¬±¸±â°ü ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Post-Marketing Pharmacovigilance and Medical Information Market to Reach US$9.6 Trillion by 2030

The global market for Post-Marketing Pharmacovigilance and Medical Information estimated at US$6.0 Trillion in the year 2024, is expected to reach US$9.6 Trillion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Spontaneous Reporting Services, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$4.2 Trillion by the end of the analysis period. Growth in the Intensified ADR Reporting Services segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Trillion While China is Forecast to Grow at 13.2% CAGR

The Post-Marketing Pharmacovigilance and Medical Information market in the U.S. is estimated at US$1.6 Trillion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Trillion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Post-Marketing Pharmacovigilance and Medical Information Market - Key Trends & Drivers Summarized

Why Is Post-Marketing Pharmacovigilance Essential in the Pharmaceutical Industry?

Post-marketing pharmacovigilance (PV) plays a critical role in ensuring drug safety and efficacy after regulatory approval, addressing potential risks, adverse events (AEs), and long-term effects of pharmaceuticals in real-world use. While clinical trials provide initial safety data, they are often limited in sample size, patient diversity, and duration, making post-market surveillance essential for detecting rare, delayed, or unforeseen adverse reactions. Regulatory agencies such as the FDA (U.S.), EMA (Europe), MHRA (UK), and PMDA (Japan) mandate ongoing drug safety monitoring, ensuring that pharmaceutical companies assess, report, and mitigate risks throughout a drug’s lifecycle.

The increasing complexity of biologics, gene therapies, and personalized medicines has heightened the need for advanced pharmacovigilance strategies. Post-marketing surveillance involves spontaneous reporting systems (SRS), electronic health record (EHR) monitoring, active surveillance, and big data analytics to track real-world drug performance. Additionally, pharmaceutical companies rely on medical information (MI) services to provide accurate, evidence-based responses to healthcare professionals (HCPs), patients, and regulatory bodies, ensuring compliance and transparency in drug safety communication.

How Are Technological Advancements Enhancing Post-Marketing Pharmacovigilance?

Technological innovations such as artificial intelligence (AI), machine learning (ML), big data analytics, and natural language processing (NLP) are revolutionizing pharmacovigilance by improving the speed, accuracy, and automation of adverse event detection. AI-powered algorithms can analyze electronic medical records, social media discussions, and patient-reported outcomes to identify potential safety signals and emerging drug-related risks more efficiently than traditional manual review processes.

Another major advancement is the integration of real-world evidence (RWE) and electronic health records (EHRs) in post-marketing safety studies. Pharmaceutical companies and regulatory agencies are increasingly leveraging RWE analytics to assess long-term safety outcomes, off-label use risks, and drug-drug interactions in broader patient populations. These insights help in making data-driven decisions regarding drug labeling updates, market withdrawals, and risk mitigation strategies.

Cloud-based pharmacovigilance platforms and automation tools are also enhancing case management, signal detection, and regulatory reporting. Many companies are adopting cloud-based adverse event (AE) management systems, allowing for real-time adverse event reporting, automated case processing, and streamlined global safety compliance. The implementation of blockchain technology in drug safety data management is also improving data integrity, security, and traceability, ensuring tamper-proof pharmacovigilance records.

What Are the Key Market Trends Driving the Expansion of Pharmacovigilance and Medical Information Services?

One of the most significant trends shaping the pharmacovigilance industry is the increasing regulatory scrutiny and evolving compliance requirements. Regulatory agencies worldwide are imposing stricter reporting timelines, transparency mandates, and risk minimization strategies, compelling pharmaceutical companies to adopt automated and AI-driven pharmacovigilance systems. The implementation of ICH E2E guidelines on pharmacovigilance planning and ISO IDMP (Identification of Medicinal Products) standards is further driving investments in integrated safety data management platforms.

The rise of patient-centric pharmacovigilance and digital health monitoring is another major trend. With the expansion of mobile health (mHealth), wearable devices, and patient-generated health data (PGHD), drug safety monitoring is becoming more proactive and real-time. Pharmaceutical companies are increasingly using smartphone apps, wearable biosensors, and online patient registries to collect continuous safety data, allowing for early risk detection and personalized pharmacovigilance approaches.

Another key trend is the outsourcing of pharmacovigilance and medical information services to contract research organizations (CROs) and business process outsourcing (BPO) providers. The increasing volume of adverse event (AE) case reports, safety signal assessments, and regulatory filings has led many pharmaceutical companies to outsource post-marketing safety operations to specialized PV service providers and technology vendors. This outsourcing model helps reduce operational costs while ensuring regulatory compliance and data-driven decision-making.

What Factors Are Driving the Growth of the Post-Marketing Pharmacovigilance and Medical Information Market?

The growth in the post-marketing pharmacovigilance and medical information market is driven by several factors, including the increasing incidence of adverse drug reactions (ADRs), rising adoption of AI-driven safety surveillance, and the expansion of global pharmacovigilance regulations. One of the primary drivers is the rising number of newly approved drugs, biosimilars, and combination therapies, which require continuous post-market monitoring to ensure long-term safety and compliance with pharmacovigilance legislation.

Another key growth factor is the expansion of personalized medicine and biologics, which present unique safety challenges due to their targeted mechanisms of action and patient-specific treatment responses. The growing adoption of cell and gene therapies, immunotherapies, and precision oncology drugs has increased the demand for advanced safety surveillance models that integrate genomic and biomarker-driven pharmacovigilance data.

The increasing focus on global harmonization of drug safety regulations is also driving the market forward. Regulatory bodies are collaborating on standardized PV frameworks, digital reporting portals, and cross-border safety data sharing to improve adverse event detection and signal management. Pharmaceutical companies must comply with evolving pharmacovigilance legislation across multiple jurisdictions, driving investments in automated compliance platforms, regulatory intelligence tools, and centralized safety databases.

Additionally, the rise of pharmacovigilance in emerging markets is contributing to market expansion. Countries such as China, India, Brazil, and South Korea are strengthening their national pharmacovigilance programs, enforcing stricter post-market surveillance mandates for both locally manufactured and imported pharmaceutical products. The demand for localized PV expertise, multilingual safety reporting, and region-specific compliance solutions is creating new growth opportunities for pharmacovigilance service providers.

As post-marketing safety requirements become more stringent, pharmaceutical companies will continue to invest in AI-powered safety monitoring, digital health analytics, and patient-centric pharmacovigilance models, ensuring that drug safety remains a top priority in the evolving global healthcare landscape.

SCOPE OF STUDY:

The report analyzes the Post-Marketing Pharmacovigilance and Medical Information market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service Type (Spontaneous Reporting Services, Intensified ADR Reporting Services, Targeted Spontaneous Reporting Services, Cohort Event Monitoring Services, EHR Mining Services); End-Use (Hospitals End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â